The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Groundbreaking study uncovers the crucial link between REM sleep patterns and Alzheimer's disease, providing new insights for ...

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

MOUNT PLEASANT, MI — Central Michigan University will team with University of Florida researchers to study Alzheimer’s ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

Delays in dreaming might be an early warning sign of Alzheimer's disease. People who take significantly longer to enter the ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Taking longer to enter the dream phase can disrupt the ability to consolidate memories and interfere with emotion regulation.

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Alzheimer’s affects millions of Americans and can have a devastating impact on finances. Some of the worst damage is done before a diagnosis is even made.